530 related articles for article (PubMed ID: 31561925)
1. The Utility of Diffusion-Weighted Imaging and Perfusion Magnetic Resonance Imaging Parameters for Detecting Clinically Significant Prostate Cancer.
Cindil E; Oner Y; Sendur HN; Ozdemir H; Gazel E; Tunc L; Cerit MN
Can Assoc Radiol J; 2019 Nov; 70(4):441-451. PubMed ID: 31561925
[TBL] [Abstract][Full Text] [Related]
2. Multiparametric MRI in detection and staging of prostate cancer.
Boesen L
Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066
[TBL] [Abstract][Full Text] [Related]
3. T2-weighted MRI-derived textural features reflect prostate cancer aggressiveness: preliminary results.
Nketiah G; Elschot M; Kim E; Teruel JR; Scheenen TW; Bathen TF; Selnæs KM
Eur Radiol; 2017 Jul; 27(7):3050-3059. PubMed ID: 27975146
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Diffusion Kurtosis Imaging Versus Standard Diffusion Imaging for Detection and Grading of Peripheral Zone Prostate Cancer.
Roethke MC; Kuder TA; Kuru TH; Fenchel M; Hadaschik BA; Laun FB; Schlemmer HP; Stieltjes B
Invest Radiol; 2015 Aug; 50(8):483-9. PubMed ID: 25867657
[TBL] [Abstract][Full Text] [Related]
5. Contribution of Dynamic Contrast-enhanced and Diffusion MRI to PI-RADS for Detecting Clinically Significant Prostate Cancer.
Tavakoli AA; Hielscher T; Badura P; Görtz M; Kuder TA; Gnirs R; Schwab C; Hohenfellner M; Schlemmer HP; Bonekamp D
Radiology; 2023 Jan; 306(1):186-199. PubMed ID: 35972360
[TBL] [Abstract][Full Text] [Related]
6. Compressed Sensing Radial Sampling MRI of Prostate Perfusion: Utility for Detection of Prostate Cancer.
Winkel DJ; Heye TJ; Benz MR; Glessgen CG; Wetterauer C; Bubendorf L; Block TK; Boll DT
Radiology; 2019 Mar; 290(3):702-708. PubMed ID: 30599102
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic value of semi-quantitative and quantitative analysis of functional parameters in multiparametric MRI of the prostate.
Hauth E; Halbritter D; Jaeger H; Hohmuth H; Beer M
Br J Radiol; 2017 Oct; 90(1078):20170067. PubMed ID: 28749167
[TBL] [Abstract][Full Text] [Related]
8. The value of ADC, T2 signal intensity, and a combination of both parameters to assess Gleason score and primary Gleason grades in patients with known prostate cancer.
Nowak J; Malzahn U; Baur AD; Reichelt U; Franiel T; Hamm B; Durmus T
Acta Radiol; 2016 Jan; 57(1):107-14. PubMed ID: 25505225
[TBL] [Abstract][Full Text] [Related]
9. Comparison of PI-RADS 2, ADC histogram-derived parameters, and their combination for the diagnosis of peripheral zone prostate cancer.
Lin WC; Westphalen AC; Silva GE; Chodraui Filho S; Reis RB; Muglia VF
Abdom Radiol (NY); 2016 Nov; 41(11):2209-2217. PubMed ID: 27364781
[TBL] [Abstract][Full Text] [Related]
10. ADC Metrics From Multiparametric MRI: Histologic Downgrading of Gleason Score 9 or 10 Prostate Cancers Diagnosed at Nontargeted Transrectal Ultrasound-Guided Biopsy.
Sadoughi N; Krishna S; McInnes MDF; Flood TA; Breau RH; Morash C; Schieda N
AJR Am J Roentgenol; 2018 Sep; 211(3):W158-W165. PubMed ID: 29995495
[TBL] [Abstract][Full Text] [Related]
11. Apparent Diffusion Coefficient (ADC) Ratio Versus Conventional ADC for Detecting Clinically Significant Prostate Cancer With 3-T MRI.
Bajgiran AM; Mirak SA; Sung K; Sisk AE; Reiter RE; Raman SS
AJR Am J Roentgenol; 2019 Sep; 213(3):W134-W142. PubMed ID: 31216201
[No Abstract] [Full Text] [Related]
12. Comparison of biparametric and multiparametric MRI in the diagnosis of prostate cancer.
Xu L; Zhang G; Shi B; Liu Y; Zou T; Yan W; Xiao Y; Xue H; Feng F; Lei J; Jin Z; Sun H
Cancer Imaging; 2019 Dec; 19(1):90. PubMed ID: 31864408
[TBL] [Abstract][Full Text] [Related]
13. Multiparametric magnetic resonance imaging for the assessment of extracapsular invasion and other staging parameters in patients with prostate cancer candidates for radical prostatectomy.
Lista F; Gimbernat H; Cáceres F; Rodríguez-Barbero JM; Castillo E; Angulo JC
Actas Urol Esp; 2014 Jun; 38(5):290-7. PubMed ID: 24387827
[TBL] [Abstract][Full Text] [Related]
14. Apparent diffusion coefficient values are superior to transrectal ultrasound-guided prostate biopsy for the assessment of prostate cancer aggressiveness.
Li C; Chen M; Wang J; Wang X; Zhang W; Zhang C
Acta Radiol; 2017 Feb; 58(2):232-239. PubMed ID: 27055916
[TBL] [Abstract][Full Text] [Related]
15. Comparing diagnostic accuracy of luminal water imaging with diffusion-weighted and dynamic contrast-enhanced MRI in prostate cancer: A quantitative MRI study.
Sabouri S; Chang SD; Goldenberg SL; Savdie R; Jones EC; Black PC; Fazli L; Kozlowski P
NMR Biomed; 2019 Feb; 32(2):e4048. PubMed ID: 30575145
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic performance of multiparametric MRI parameters for Gleason score and cellularity metrics of prostate cancer in different zones: a quantitative comparison.
Gao J; Zhang Q; Zhang C; Chen M; Li D; Fu Y; Lv X; Zhang B; Guo H
Clin Radiol; 2019 Nov; 74(11):895.e17-895.e26. PubMed ID: 31337490
[TBL] [Abstract][Full Text] [Related]
17. Effect of observation size and apparent diffusion coefficient (ADC) value in PI-RADS v2.1 assessment category 4 and 5 observations compared to adverse pathological outcomes.
Abreu-Gomez J; Walker D; Alotaibi T; McInnes MDF; Flood TA; Schieda N
Eur Radiol; 2020 Aug; 30(8):4251-4261. PubMed ID: 32211965
[TBL] [Abstract][Full Text] [Related]
18. Quantitative diffusion-weighted imaging and dynamic contrast-enhanced characterization of the index lesion with multiparametric MRI in prostate cancer patients.
Yuan Q; Costa DN; Sénégas J; Xi Y; Wiethoff AJ; Rofsky NM; Roehrborn C; Lenkinski RE; Pedrosa I
J Magn Reson Imaging; 2017 Mar; 45(3):908-916. PubMed ID: 27442039
[TBL] [Abstract][Full Text] [Related]
19. Quantitative Analysis of Prostate Multiparametric MR Images for Detection of Aggressive Prostate Cancer in the Peripheral Zone: A Multiple Imager Study.
Hoang Dinh A; Melodelima C; Souchon R; Lehaire J; Bratan F; Mège-Lechevallier F; Ruffion A; Crouzet S; Colombel M; Rouvière O
Radiology; 2016 Jul; 280(1):117-27. PubMed ID: 26859255
[TBL] [Abstract][Full Text] [Related]
20. Quantitative diffusion-weighted imaging and dynamic contrast-enhanced MR imaging for assessment of tumor aggressiveness in prostate cancer at 3T.
Fukunaga T; Tamada T; Kanomata N; Takeuchi M; Ueda Y; Miyaji Y; Kido A; Yamamoto A; Sone T
Magn Reson Imaging; 2021 Nov; 83():152-159. PubMed ID: 34454006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
